598 related articles for article (PubMed ID: 35391713)
1. Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.
Chung KW; Cho YE; Kim SJ; Hwang S
Arch Pharm Res; 2022 Apr; 45(4):229-244. PubMed ID: 35391713
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
3. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
4. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Lee C; Kim J; Jung Y
Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
[TBL] [Abstract][Full Text] [Related]
5. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
6. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis.
Rui L; Lin JD
Annu Rev Nutr; 2022 Aug; 42():91-113. PubMed ID: 35584814
[TBL] [Abstract][Full Text] [Related]
8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
9. Recent updates on targeting the molecular mediators of NAFLD.
Wang J; Wang L; Zhang XJ; Zhang P; Cai J; She ZG; Li H
J Mol Med (Berl); 2023 Feb; 101(1-2):101-124. PubMed ID: 36792729
[TBL] [Abstract][Full Text] [Related]
10. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
Malhotra P; Aloman C; Ankireddy A; Khadra H; Ooka K; Gill RK; Saksena S; Dudeja PK; Alrefai WA
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G376-G385. PubMed ID: 28774869
[TBL] [Abstract][Full Text] [Related]
11. Immune-metabolic interactions in homeostasis and the progression to NASH.
Hoogerland JA; Staels B; Dombrowicz D
Trends Endocrinol Metab; 2022 Oct; 33(10):690-709. PubMed ID: 35961913
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
14. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Soejima Y; Fukusato T
World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421
[TBL] [Abstract][Full Text] [Related]
15. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease.
Wiering L; Subramanian P; Hammerich L
Cell Mol Gastroenterol Hepatol; 2023; 15(6):1277-1292. PubMed ID: 36828280
[TBL] [Abstract][Full Text] [Related]
17. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
Musso G; Saba F; Cassader M; Gambino R
Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.
Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908
[TBL] [Abstract][Full Text] [Related]
19. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
Subramanian P; Hampe J; Tacke F; Chavakis T
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
[TBL] [Abstract][Full Text] [Related]
20. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Tillman EJ; Rolph T
Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
